Crism Therapeutics Corporation (CRTX)

ORD NPV

Sell: 8.00p|Buy: 9.50p|Change: 0 (0%)

Open

8.75p

Previous close

8.75p

Trade high

9.10p

Volume

53,429

Year high

29.40p

Year low

5.64p

Dividend yield

–

Market capitalisation

£4.47 mn

P/E ratio

0.03

ISIN

VGG042401262

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPPand can be used with Dividend reinvestment

Share price

Performance 12/12/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Crism Therapeutics Corporation	0.00
FTSE AIM All Share	+ 0.18
More...

Company profile

Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation anddevelopment.

Sector

Healthcare

News

Recent trades

Date	Time	Price	Quantity	Value (£)
12/12/2025	03:47:41	9.0481	5,526	500.00
12/12/2025	02:25:06	8.3	33	2.74
12/12/2025	02:06:06	9.0481	1,000	90.48
12/12/2025	01:04:52	8.3	442	36.69
12/12/2025	12:51:27	8.3	7,749	643.17

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.